Nutritional Neuroscience最新文献

{"title":"An updated systematic review and appraisal of the pathophysiologic mechanisms of probiotics in alleviating depression.","authors":"Nur Najibah Yusra Sulaiman, Nazifa Batrisyia Mohamad Nizam, Nurul Ain Mohd Noor, Siong Meng Lim, Kalavathy Ramasamy, Aied Mohammed Alabsi, Muhamad Fareez Ismail","doi":"10.1080/1028415X.2025.2531357","DOIUrl":"https://doi.org/10.1080/1028415X.2025.2531357","url":null,"abstract":"<p><p>Gut-brain axis has emerged as a promising strategy for managing depression. Probiotic supplements, which modulate the gut microbiome, are suggested to enhance gut-brain communication and improve depressive symptoms and cognitive function. However, the acceptance of probiotics in managing depression remains contentious. This study aimed to evaluate the effects of probiotics on depression through meta-analysis and to assess their mechanisms of action, focusing on changes in gut microbial composition and neural mechanisms. A total of 12 randomized controlled trials from PubMed, Web of Science, and Scopus, up to January 1, 2024, were included. Nine studies consistently demonstrated improvements in depressive symptoms, gut microbiota, inflammatory markers, cognitive function, and mood regulation. The meta-analysis indicated a significant reduction in depressive symptoms with probiotics compared to placebo, with a mean difference of - 1.94 (95% CI = -3.56 to - 0.32, <i>p</i> = 0.02, I₂ = 69%). The Hamilton Depression Rating Scale (HAM-D), which showed substantial improvement, with a mean difference of - 3.27 (95% CI = -6.42 to - 0.12, <i>p</i> = 0.04, I₂ = 82%), is a preferred tool for further studies due to its comprehensive symptom coverage and strong psychometric properties. Probiotic strains such as <i>Lactobacillus plantarum</i> subspecies JYLP-326 and <i>Bifidobacterium breve</i> CCFM1025 were particularly effective, while multi-strain probiotics generally showed more consistent effects than single-strain interventions. Probiotics show promising potential in alleviating depression through their anti-inflammatory effects, gut microbiota modulation, cognitive function enhancement, and possible influence on brain structure and neurotransmitter systems. Despite some variability in trial results, this review provides updated insights for medical practitioners, highlighting probiotics as a viable treatment option for depression.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"1-21"},"PeriodicalIF":3.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain-gut co-management: probiotic LAB improves mental health and further reduces disease activity in ulcerative colitis patients with emotional disturbance.","authors":"Xiaoning Liu, He Zhou, Jiaqi Zhang, Ruixia Li, Jie Liang","doi":"10.1080/1028415X.2025.2527224","DOIUrl":"https://doi.org/10.1080/1028415X.2025.2527224","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with Ulcerative Colitis (UC) are susceptible to emotional disturbance, which could negatively affect the condition itself. Meanwhile, certain probiotics have been proven to alleviate emotional disturbance, and improve disease status in UC. Yet little is known about probiotic's efficacy on UC patients with emotional disturbance.</p><p><strong>Methods: </strong>Sixty patients were recruited, diagnosed as having mild to moderate UC and with anxiety and/or depression disorders. Participants were then randomly assigned to a control group receiving conventional treatment (mesalazine ≤4 g) or a probiotic group receiving probiotic LAB combined with conventional treatment for 8 weeks. At the commencement and conclusion of the study, questionnaires were administered to determine patients' improvements in emotional disturbance and disease activity. Stool samples were collected concurrently to estimate alterations in fecal microbiota.</p><p><strong>Results: </strong>At 8 weeks, 65.4% of patients in the probiotic group had relieved anxiety disorder, compared to 34.6% in the control group (<i>p</i> = 0.03). Improvement on depression was higher in the probiotic group (53.8%) than the control group (30.8%), though without significant differences (<i>p</i> = 0.09). Both groups had reduced Modified Mayo Scores (MMS). Mayo Endoscopic Sub-score (MES) dropped significantly in the probiotic group (<i>p</i> = 0.02) but not in the control group. Fecal samples sequenced by 16S rRNA showed a significant increase in <i>Firmicutes</i> after receiving probiotics, and no significant differences were detected in the control group.</p><p><strong>Discussion: </strong>This randomized trial demonstrated that supplementation with probiotic LAB could restore the abundance of <i>Firmicutes</i>, improve anxiety disorder, and reduce MES in UC patients with emotional disturbance.Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT04006977, date October 2019.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"1-12"},"PeriodicalIF":3.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A U-shaped association between composite dietary antioxidant index and migraine in US adults: a nationwide cross-sectional study.","authors":"Tianqi Zuo, Jingya Yang, Yiyan Sun, Xiaotong Li, Hongyun Wu, Kunqi Han, Leiyong Zhao, Wei Peng","doi":"10.1080/1028415X.2024.2423574","DOIUrl":"10.1080/1028415X.2024.2423574","url":null,"abstract":"<p><strong>Background: </strong>The field of dietary therapies for migraine has grown in popularity. Less research has been conducted to establish the relationship between migraine and the composite dietary antioxidant index (CDAI), a crucial indicator for evaluating the overall combined effects of multiple dietary antioxidants. Therefore, this study addressed this gap based on the National Health and Nutrition Examination Survey (NHANES) database.</p><p><strong>Methods: </strong>Multivariate logistic regression equations were used to investigate the relationship between CDAI and migraine, and smoothed-fitted curves were plotted. After a nonlinear relationship was discovered, the recursive algorithm and a two-stage linear regression model were employed to calculate the turning point. Additional stratified analyses were performed to explore differences between populations.</p><p><strong>Results: </strong>This study included a total of 9,190 participants aged 20 years old or older. A U-shaped association was observed between the CDAI and migraine, with an inflection point of 0.2. They were negatively correlated before the inflection point with OR of 0.93 (95% CI = 0.88-0.97) and positively correlated after the inflection point with OR of 1.04 (95% CI = 1.01-1.07). This U-shaped relationship persisted among people aged <60 and ≥60 years, women, and people with BMI <30 and ≥30.</p><p><strong>Conclusions: </strong>We identified a U-shaped association between CDAI and migraine in the U.S. adult population. Further case-control studies and experimental research are needed to explore the underlying mechanisms of action.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"796-806"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between mealtime distribution of macronutrient and mental health in apparently healthy Iranian adults: a cross-sectional study.","authors":"Aliyu Tijani Jibril, Kurosh Djafarian, Sakineh Shab-Bidar","doi":"10.1080/1028415X.2024.2425567","DOIUrl":"10.1080/1028415X.2024.2425567","url":null,"abstract":"<p><p>Mental health (MH) disorders are one of the most prevalent global public health issues for a significant portion of the population. The aim of this study was to investigate the relationship between the mealtime distribution of macronutrients and MH in Iranian adults. We used a convenience sampling technique to perform this cross-sectional study. The Depression, Anxiety, and Stress Scale (DASS-21) was used to assess the MH outcome. Dietary consumption was assessed using multiple 24-hour dietary recalls. The coefficient of variation (CV) was then used to compute the macronutrient distribution at mealtime. In all, 54.6%, 53.9%, and 56.6% were classified as having anxiety, depression, and stress symptoms, respectively. The CV scores for carbohydrate were relatively evenly distributed across all meal times, with a mean of 0.38, 0.38, and 0.39 for breakfast, lunch, and dinner, respectively. We observed no significant association between the mealtime distribution of carbohydrates and mental health indices in any of the analyzed models. However, a more skewed distribution of protein intake towards dinner (i.e. a higher protein CV value) was positively associated with anxiety (OR: 1.69; CI: 1.02-2.78) and stress symptoms (OR: 1.93; CI: 1.17-3.16). We also observed a significant association between fat distribution and depression symptoms, with subjects in tertile 2 having higher odds of depression compared to T1 (OR: 1.63; CI: 1.00-2.63). In conclusion, a skewed distribution of protein and fat intake may be associated with mental health problems. Future studies are warranted to validate these findings and gain a better understanding of the underlying mechanisms.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"819-828"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroprotective effect and possible mechanisms of the extract of ginkgo biloba for spinal cord injury in experimental animal: a meta-analysis and systematic review.","authors":"Zi-Ming Wu, Wei Wu, Xing Ding, Qian Feng, Bi-Meng Zhang, Hong-Shen Wang, Xue-Jun Cui, Min Yao","doi":"10.1080/1028415X.2024.2425643","DOIUrl":"10.1080/1028415X.2024.2425643","url":null,"abstract":"<p><p>Spinal cord injury (SCI) is a major challenge in the medical community because of its difficulty in treatment and poor prognosis. Extract of ginkgo biloba (EGb) has been widely used in the prevention and treatment of age-related neurosensory disease, which is considered to have the effect of neuroprotection. We performed a systematic review to evaluate the neurobiological roles of EGb for treating SCI in rats. Pubmed, Embase, Sinomed and China National knowledge Infrastructure were searched from their inception dates to April 2024, and 30 articles were included. The quality score of the included studies ranged from 4 to 7 out of 10 points, and all of them were randomization. It was shown that after SCI, EGb administration could significantly improve motor function (WMD = 2.09 [1.59, 2.59], <i>p</i> < 0.00001). Subgroup analysis concluded that EGb at the doses of 10-50 mg/kg improved the motor function to the greatest extent. In comparison with the control group, EGb administration could reduce lipid peroxidation and inhibit inflammation (MDA: SMD = -1.43 [-5.05,2.20], <i>p</i> < 0.00001; iNOS: WMD = -22.17 [-35.45, -8.90], <i>p</i> < 0.00001). In addition, this review suggested that EGb can antagonize inflammation, reduce oxidative stress to inhibit the lipid peroxidation and resistance to apoptosis, promote nerve growth and reduce myelin loss on SCI. Preclinical grade suggests that, collectively, EGb may be a promising natural neuroprotective agent on SCI with unique advantages and mechanisms of action. More clinical randomized, blind controlled trials are also needed to confirm the neuroprotective effect of EGb on SCI.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"840-853"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.","authors":"Sara Keramatzadeh, Seyed Ahmad Hosseini, Nastaran Majdinasab, Bahman Cheraghian, Marzie Zilaee","doi":"10.1080/1028415X.2024.2425649","DOIUrl":"10.1080/1028415X.2024.2425649","url":null,"abstract":"<p><strong>Objectives: </strong>Resveratrol, a polyphenol found in grapes, has been studied extensively for its potential benefits on metabolic markers and inflammation. While promising results have been observed in animal studies and some human trials, the overall evidence is mixed. Moreover, elevated inflammatory markers have been closely linked to more severe symptoms of Multiple Sclerosis (MS). Therefore, strategies to reduce systemic inflammation could potentially improve outcomes for MS patients. So we aimed to examine the effectiveness of resveratrol supplementation on inflammatory markers in patients with Multiple sclerosis (MS), in a randomized placebo-controlled double-blinded parallel clinical trial.</p><p><strong>Methods: </strong>A total of 55 subjects with MS were enrolled in this study and randomly assigned to the two groups who were supplemented with resveratrol at a dose of 500 mg/day or received placebo capsules for 8 weeks. Tumor necrosis factor-alpha (TNF-α), Malondialdehyde (MDA), fasting blood sugar (FBS), triglycerides, total cholesterol, low-density lipoprotein - cholesterol (LDL-C), high-density lipoprotein - cholesterol (HDL-C), and the degree of fatigue were measured at baseline and after the intervention.</p><p><strong>Results: </strong>Resveratrol treatment significantly decreased TNF-α (<i>P</i> < 0.001), and MDA (<i>P</i> < 0.001) compared to the placebo. The respective increase and decrease in FBS and HDL levels were seen in both groups, while the change in participants receiving resveratrol was significantly less pronounced. Changes in the levels of TG and fatigue scale remained unchanged.</p><p><strong>Conclusion: </strong>This study showed that resveratrol supplementation exerted anti-inflammatory and anti-oxidant effects in patients with MS.<b>Trial registration:</b> Iranian Registry of Clinical Trials identifier: IRCT20230315057731N1.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"854-862"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of green tea catechins on the development of Parkinson's disease symptoms in a transgenic A53T mouse model.","authors":"Elizabeth Riegelman, Kathy Xue, Jia-Sheng Wang, Lili Tang","doi":"10.1080/1028415X.2024.2427753","DOIUrl":"10.1080/1028415X.2024.2427753","url":null,"abstract":"<p><p><b>Objectives:</b> This study aimed to evaluate the effects of green tea catechins on the prevention of Parkinson's disease neurobehavioral symptoms and α-synuclein blood plasma concentration in a hemizygous transgenic A53T mouse model.<b>Methods:</b> Thirty 6-month-old male mice were randomly assigned to three groups (<i>n</i> = 10/group): control, low-dose, and high-dose, receiving green tea polyphenol (GTP) treatment in their drinking water at 0%, 0.5%, and 1.5%, respectively, over a 90-day period. The efficacy of <i>ad libitum</i> dosing was assessed by analyzing the bioaccumulation of tea catechins in urine samples collected from metabolic cages on days 0, 30, 60, and 90, using LC/Q-TOF analysis. PD-related behavioral impairments were measured with open field and rotarod performance tests on days 0, 45, and 90. On day 90, plasma α-synuclein levels were analyzed via enzyme-linked immunosorbent assay (ELISA) to assess treatment effects.<b>Results:</b> Circulating tea catechin metabolites were detected in treated groups by day 30, with levels progressively increasing through day 90. By day 90, control mice exhibited significant deficits in rotarod performance, while both low- and high-dose groups maintained or improved their maximum time on the rotarod. Open field testing indicated reduced anxiety-related behavior in control mice compared to treated groups. ELISA analysis revealed significantly lower circulating α-synuclein levels in high-dose mice compared to controls.<b>Conclusion:</b> Our findings indicate that sustained administration of tea catechins significantly reduces circulating α-synuclein levels in blood plasma, improves motor coordination in a dose-dependent manner, and modulates anxiety-related behaviors in a PD mouse model.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"863-879"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of <i>Bacopa Monnieri</i> (Brahmi) in the management of schizophrenia: a systematic review.","authors":"Gideon Opeyemi Ayilara, Bamidele Victor Owoyele","doi":"10.1080/1028415X.2024.2421782","DOIUrl":"10.1080/1028415X.2024.2421782","url":null,"abstract":"<p><p>Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population. Despite advancements in pharmacological treatments, many patients with schizophrenia continue to experience significant impairments, and approximately one-third of these patients do not respond to antipsychotic drugs. However, various studies have demonstrated the potential benefits of herbs in managing schizophrenia due to the diverse biological activities of phytochemicals, including neuroprotective activity, anti-oxidant potential, modulation of neurotransmission, and anti-inflammatory activity. <i>Bacopa monnieri</i> (Brahmi) is a widely studied herb used in the treatment of the central nervous system. This study conducted a systematic review to determine the effectiveness of Brahmi in managing schizophrenia. PubMed, Scopus, Web of Science, and Cochrane databases were searched between February and March, 2024. A total of 103 articles were found, with only 9 studies meeting the eligibility criteria. Data analysis was done by using themes. The review found that Brahmi could reverse positive, negative, and cognitive symptoms of schizophrenia. It does this by changing the glutamatergic pathway and GABAergic transmission, lowering MDA levels, raising GSH levels, slowing down the activity of acetylcholinesterase (AchE), and maintaining the density of neurones. It is recommended that additional research elucidating the effects of Brahmi in other models of schizophrenia and the possible mechanisms of action be conducted.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"788-795"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a prebiotic-rich diet and/or probiotic supplements on human cognition: Secondary outcomes from the 'Gut Feelings' randomised controlled trial.","authors":"Tanya M Freijy, Lachlan Cribb, Georgina Oliver, Najwa-Joelle Metri, Rachelle S Opie, Felice N Jacka, Jason A Hawrelak, Julia J Rucklidge, Chee H Ng, Jerome Sarris","doi":"10.1080/1028415X.2024.2425570","DOIUrl":"10.1080/1028415X.2024.2425570","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence indicates that gut microbiota-targeted interventions may lead to improvements in cognition. We assessed whether a prebiotic-rich dietary intervention, probiotic supplement, or synbiotic combination of both would improve human cognition, as part of the 'Gut Feelings' trial.</p><p><strong>Methods: </strong>An 8-week, 2 × 2 factorial randomised controlled trial was conducted on 118 adults with low mood and potential for dietary improvement. Treatment arms: (1) probiotic supplement and diet-as-usual (probiotic group); (2) high-prebiotic diet and placebo supplement (prebiotic diet group); (3) probiotic supplement and high-prebiotic diet (synbiotic group); and (4) placebo supplement and diet-as-usual (placebo group). At baseline and 8-weeks, the Cogstate Brief Battery was administered, testing processing speed, attention, visual learning, and working memory. Data were analysed using Bayesian linear regression.</p><p><strong>Results: </strong>We found weak evidence that the probiotic improved working memory (Cohen's <i>d</i> = -0.32, 95% CI: -0.67, 0.03; posterior probability [post. prob] of benefit: 96%). For the other treatments, there was little or no evidence of cognitive improvement. We found weak evidence that the prebiotic diet impaired processing speed (<i>d</i> = 0.25, 95% CI: -0.02, 0.51; post. prob of harm: 97%). There was little indication of a synergistic interaction between the probiotic and prebiotic diet.</p><p><strong>Conclusion: </strong>We found suggestive evidence of a probiotic-induced improvement in working memory, and prebiotic-induced impairment in processing speed. However, the evidence remains inconclusive regarding any cognitive benefit or harm induced by the probiotic, prebiotic diet, or synbiotic treatments. Larger intervention studies are recommended, with inclusion of neuroimaging or electrophysiology measures.<b>Trial Registration:</b> Australian New Zealand Clinical Trials Registry (ACTRN12617000795392; registered 31 May 2017).</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"829-839"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of whey-derived lactopeptide β-lactolin on cognitive performance in mild cognitive impairment: a randomized, double-blind, placebo-controlled trial.","authors":"Kentaro Umeda, Keiko Kobayashi, Ayana Kanatome, Yoshie Sugimura, Yasuhisa Ano, Hiroaki Suzuki, Takafumi Fukuda, Eisaku Okada, Shigeki Muto","doi":"10.1080/1028415X.2024.2428396","DOIUrl":"10.1080/1028415X.2024.2428396","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effects of a long-term intervention with β-lactolin, a tetrapeptide (sequence: glycine-threonine-tryptophan-tyrosine) derived from milk, on cognitive performance in individuals with mild cognitive impairment (MCI).</p><p><strong>Methods: </strong>A randomized, double-blind, placebo-controlled trial was conducted. We recruited 48 participants aged 50 years or older with the Japanese version of the Mini-Mental State Examination (MMSE-J) score of 24-28 and a Clinical Dementia Rating (CDR) score of 0.5. Participants were administered β-lactolin (1.8 mg daily) or placebo for 24 weeks. The primary outcomes were the MMSE-J and the Japanese version of the Montreal Cognitive Assessment (MoCA-J) scores for cognitive function.</p><p><strong>Results: </strong>A total of 422 individuals were screened, 48 of whom were included in this study. The MMSE-J and MoCA-J scores showed no significant differences between the groups. In the intra-group comparison of the MoCA-J delayed recall score, a significant difference was observed in the β-lactolin group after 12 and 24 weeks of intervention (<i>p</i> = 0.0256, <i>p</i> = 0.0175, respectively). Furthermore, the subgroup analysis stratified for females only showed a significant difference in MoCA-J total score in the β-lactolin group after 24 weeks of intervention (<i>p</i> = 0.0253).</p><p><strong>Conclusion: </strong>β-lactolin intake does not significantly improve cognitive function in MCI in an inter-group comparison; nevertheless, the MoCA-J delayed recall score was significantly improved in the β-lactolin group. The number of participants was lower than planned, limiting the confirmation of the effectiveness of β-lactolin on MCI. This report demonstrated the effect size of β-lactolin intervention in MCI, contributing insights for future research.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"880-890"},"PeriodicalIF":3.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}